Clinical Outcome in Patients With Syringomyelia（COPSM）

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-16

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to determine the clinical spectrum and natural progression of Syringomyelia (SM) and related disorders in a prospective single center study, identify digital, imaging and molecular biomarkers that can assist in diagnosis and therapy development and study the etiology and molecular mechanisms of these diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcriptomic Study of Adult Population With Marfan Syndrome

NCT05700175

Marfan Syndrome Marfan's Syndrome With Cardiovascular Manifestations

RECRUITING

A Multicenter Observational Cohort of Degenerative Spine Diseases in China（DSDC）

NCT05867732

Degenerative Spine Diseases

COMPLETED

Large-scale Multi-omics Analysis of Cerebrospinal Fluid

NCT06636201

Aging

RECRUITING

Gut Microbiota in Patients With Moyamoya Disease

NCT04890782

Moyamoya Disease Gut Microbiota

UNKNOWN

Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)

NCT07266051

NMOSD

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Syringomyelia is a chronic central spinal cord injury, which is characterized by dilation of the central canal of the spinal cord. At present, the treatment of syringomyelia is mainly through surgical decompression to restore the disturbance of cerebrospinal fluid circulation. Due to the heterogeneity of the etiology of syringomyelia, almost all published studies on the clinical outcome and prognostic factors of syringomyelia are relatively limited, and most of them are retrospective. It is not clear which is the most reliable predictor of clinical outcome. Therefore, the researchers conducted this prospective cohort study to identify the occurrence, development and outcome of syringomyelia and determine the main prognostic factors through clinical scales, biomarkers and electrophysiology.

At study visits a standardized clinical examination will be performed including application of clinical rating scales. At all study visits, patients will be asked to donate biosamples; biomaterial collection is optional and participants can elect to participate in sampling of blood, urine, CSF, and/or a muscle biopsy.

Optionally, additional examinations may be performed including imaging, neurophysiological examination, analysis of patient or observer reported outcomes and analysis to characterize molecular biomarkers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Syringomyelia/Hydromyelia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

syringomyelia group

high throughput sequencing and electromyography

Intervention Type DIAGNOSTIC_TEST

Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics

Other neurodegenerative diseases

such as hydrocephalus

high throughput sequencing and electromyography

Intervention Type DIAGNOSTIC_TEST

Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics

Normal group

high throughput sequencing and electromyography

Intervention Type DIAGNOSTIC_TEST

Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

high throughput sequencing and electromyography

Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who was diagnosed as syringomyelia including: Chiari malformation， Basilar Impression， subarachnoid obstruction， patient not received surgical or interventional treatment before， patient willing and able to participate in the registry，
* Hydrocephalus or other neurodegenerative disease and normal subjects.

Exclusion Criteria

* patient received surgical treatment or interventional treatment before
* patient is pregnant
* patient unable to complete follow-up
* patient with other spinal lesions
* other nervous system diseases

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes